Public trial registry of the CCC-Munich

Trial ACCEPT

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
ACCEPT
World
Full title
:

Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
KUM - Med3 - Medizinische Klinik und Poliklinik III Lmu
Indications
Classification Code Description
ICD-10-GM C25.- Bösartige Neubildung des Pankreas
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
II
Status
World
Status
:
Recruitment active
Votes
World
Institutional review board - vote
:
Positive
World
BfArM - vote
:
Positive
World
BfArM - reference number
:
4038426
Initiiation & lock
World
Date of lock (planned / actual)
:
2015-07-01 / Unknown
Therapy
World
Therapy line
:
1
Documents Public
Document Language Version Uploaded/Updated at
World Trial Protocol de Keine Angabe 2015-06-15 13:47:37 UTC
Participants
Function Prename Surname Organization
World Responsible contact Volker Heinemann KUM - Med3 - Medizinische Klinik und Poliklinik III Magnifier
World Principal Investigator Volker Heinemann KUM - Med3 - Medizinische Klinik und Poliklinik III Magnifier
World Sponsor - Klinikum der Universität München Magnifier